周二,Cantor Fitzgerald重申了对Avita Medical Ltd.(纳斯达克股票代码:RCEL)的增持评级和21.00美元的目标价,这意味着相对于当前11.75美元的价格有近80%的上涨空间。根据InvestingPro数据,分析师的目标价范围从11.38美元到20.94美元不等,该股票在过去一年中显示出显著的价格波动。
HEFEI, Dec 26 (China Economic Net) - The International Molecular Pathology Training Program hosted by the Ministry of Science and Technology of China concluded at Anhui Medical University on Dec 24.